Annexon, Inc. 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a crossroads between scientific breakthrough and financial exhaustion. Annexon has successfully built a differentiated scientific moat by targeting the start of the classical complement cascade, potentially offering a more complete protection than downstream inhibitors. The upcoming 2026 catalyst window—comprising the tanruprubart BLA and vonaprument Phase 3 results—will determine if the company can transition from a clinical-stage burn to a commercial-stage powerhouse. Investors must weigh the potential of a first-in-class standard of care against the reality of a fragile balance sheet. The presence of $556.1 million in federal NOLs provides a massive potential tax shield, but this asset is vulnerable to the very equity raises the company may need to survive until 2027. The ultimate outcome depends on whether the FDA accepts the current data packages or mandates further, costly trials that would accelerate the cash burn beyond the current runway.